Clinical Trial Update: Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating catumaxomab as consolidation therapy for ovarian cancer patients in second or third clinical remission has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Removab (catumaxomab)

Snippet

Sponsor: Grupo Español de Investigación en Cáncer de Ovario | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED